Literature DB >> 1715283

Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain.

V P Chekhonin1, A V Kabanov, Y A Zhirkov, G V Morozov.   

Abstract

A method for targeted delivery of neuroleptics from blood in brain based on using Fab-fragments of antibodies to antigens of brain glia cells (acid gliofibrillar antigen and alpha 2-glycoprotein) is suggested. The essence of the technique is that the molecule of neuroleptic (trifluoperazine) is conjugated with Fab-fragments of these antibodies. The conjugate thus obtained is modified by stearoylchloride in the system of Aerosol OT reversed micelles in octane. The study of the distribution of 125I-labelled conjugates in the rat organism after intracordial introduction is performed. On the contrary to the nonmodified conjugates and conjugate, containing fatty acylated Fab-fragments of antibodies, nonspecific to the rat brain, the conjugate of trifluoperazine with stearoylated Fab-fragments of antibodies to neurospecific antigens accumulate in brain tissues. The drastic increase of the neuroleptic activity of trifluoperazine resulting from its coupling with stearoylated Fab-fragments of antiglial antibodies is observed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715283     DOI: 10.1016/0014-5793(91)80037-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Polyethylene-glycolated immunoliposomes specific for astrocytes.

Authors:  V P Chekhonin; Yu A Zhirkov; O I Gurina; I A Ryabukhin; S V Lebedev; I A Kashparov; D V Blinov; T B Dmitrieva
Journal:  Dokl Biochem Biophys       Date:  2003 Jul-Aug       Impact factor: 0.788

Review 2.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 4.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

5.  Drug transport into the central nervous system: using newer findings about the blood-brain barriers.

Authors:  William A Banks
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

Review 6.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 7.  Micellar nanocarriers: pharmaceutical perspectives.

Authors:  V P Torchilin
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.200

8.  Transepithelial transport of tyramine across filter-grown MDCK cells via a poly(D-lysine) carrier.

Authors:  M E Taub; J Wan; W C Shen
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

9.  Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.

Authors:  William A Banks; Susan A Farr; John E Morley; Kathy M Wolf; Valeria Geylis; Michael Steinitz
Journal:  Exp Neurol       Date:  2007-05-22       Impact factor: 5.330

Review 10.  Brain delivery of proteins via their fatty acid and block copolymer modifications.

Authors:  Xiang Yi; Alexander V Kabanov
Journal:  J Drug Target       Date:  2013-12       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.